Clinical trialPhase 1Unknown
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
IMM2510, a Multi-Center, Open-Label, Dose Escalation and Cohort Expansion Phase I Clinical Study for Advanced Solid Tumors
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 18 August 2021
- Listed end
- October 2024
- Enrollment
- 108 participants
- Sites
- 4
- Primary outcomes
- AEs; DLT; MTD and RP2D; Changes in Laboratory Test Result; Changes in Electrocardiogram
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 2 August 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This trial is a first-in-human, open-label, multi-center, dose escalation phase 1a study followed by cohort expansion phase 1b study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced solid tumors.
Detailed description public domain (ClinicalTrials.gov)
IMM2510 is administered via intravenous infusion every 2 weeks up to 52 weeks. Phase 1a Dose Escalation: using accelerated titration followed by 3+3 dose escalation design to explore the maximum tolerated dose (MTD) and the recommended dose (RDE). Phase 1b Cohort Expansion: planing to enroll at least 60 patients with different advanced solid tumors (multiple cohorts) to further observe the safety and antitumor activity of IMM2510, and to determine the recommended phase II dose (RP2D).